Edwards Lifesciences Corporation (EW) News

Edwards Lifesciences Corporation (EW): $121.02

1.36 (+1.14%)

POWR Rating

Component Grades













Filter EW News Items

EW News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EW News Highlights

  • For EW, its 30 day story count is now at 64.
  • Over the past 21 days, the trend for EW's stories per day has been choppy and unclear. It has oscillated between 3 and 12.
  • The most mentioned tickers in articles about EW are BIO, CLDX and CRNX.

Latest EW News From Around the Web

Below are the latest news stories about Edwards Lifesciences Corp that investors may wish to consider to help them evaluate EW as an investment opportunity.

Artificial Organ Market Still Has Room to Grow | Emerging Players Baxter International, Edward Lifesciences, Abiomed

The latest research on Global Artificial Organ Report 2021 offered by HTF MI provides a comprehensive investigation into the geographical landscape, industry size along with the revenue estimation of the business. Additionally, the report also highlights the challenges impeding market []

iCrowdNewswire | September 14, 2021

Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences Corporation ( NYSE:EW ) led the NYSE gainers with a relatively large price hike in the past couple...

Yahoo | September 14, 2021

Nitinol Medical Devices Market Insights, Trends, Top Industry Players and Future Development Status by 2025 | Medtronic Medical Devices, Edwards Lifesciences, Abbott Hospital & Health Care

A2Z Market Research announces the release of the Nitinol Medical Devices Market research report. The global Nitinol Medical Devices market research is predicted to record a 7.20% CAGR during the review period 2021-2027. Global "Nitinol Medical Devices Market" 2021 report provides

OpenPR | September 13, 2021

Transradial Access Market Analysis and Forecast 2028 By Keyplayers Stryker, CARDINAL HEALTH, Angiodynamics Inc., BD, Terumo Corporation, Teleflex Incorporated, Smiths Group plc, MEDTRONIC, Boston Scientific Corporation, Edwards Lifesciences Corporation

Transradial access market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 2,413.79 million by 2027 growing at a CAGR of 8.80% in the

OpenPR | September 10, 2021

Artificial Tissue Heart Valve Market Introducing New Industry Dynamics through Swot Analysis 2021|Edwards Lifesciences, Medtronic, Abbott, Livanova, Boston Scientific, Cryolife

Artificial Tissue Heart Valve Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors.

OpenPR | September 9, 2021

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi''s Pemphigus Trial Disappointment, Humanigen''s COVID-19 Drug Denied Emergency Use Authorization

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE: ABT ) Candel Therapeutics, Inc. (NASDAQ: CADL ) (announced its quarterly results) Cardiol Therapeutics Inc. (NASDAQ: CRDL ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) DexCom, Inc. (NASDAQ: DXCM ) Edwards Lifesciences Corporation (NYSE: EW ) ICU Medical, Inc. (NASDAQ: ICUI ) (announced a deal to buy Smiths Medical division for $2.35 billion in cash) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Kadmon Holdings, Inc. (NASDAQ: KDMN ) - announced a deal to be bought by S...

Benzinga | September 9, 2021

The Daily Biotech Pulse: MacroGenics'' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA''s FDA Nod

Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ) Axonics, Inc. (NASDAQ: AXNX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Candel Therapeutics, Inc. (NASDAQ: CADL ) (announced completion of patient enrollment in the pivotal phase 3 study of CAN-2409 in prostate cancer) Cardiol Therapeutics Inc. (NASDAQ: CRDL ) (announced addition to its board) Caribou Biosciences, Inc. (NASDAQ: CRBU ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) Edwards Lifesciences Corporation (NYSE: EW ) Er...

Benzinga | September 8, 2021

Edwards Lifesciences Corporatio Consensus Indicates Potential -1.4% Downside

Edwards Lifesciences Corporatio found using ticker (EW) now have 22 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 135 and 71 with the average target price sitting at 119.36. Given that the stocks previous close was at 121.07 this would indicate that there is a downside of -1.4%. The 50 day moving average now sits at 114.21 and the 200 day MA is 97.83. The market cap for the company is $76,594m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="EW" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Eur...

DirectorsTalk | September 8, 2021

Houston We Have is now fully funded to trial its ECHOiQ heart disease detection AI program

Houston We Have (ASX:HWH) is teaming up with healthcare giant Edwards Lifesciences (NYSE:EW) to fully fund its aortic stenosis clinical Read More The post Houston We Have is now fully funded to trial its ECHOiQ heart disease detection AI program appeared first on Stockhead .

Stockhead | September 7, 2021

Analysis on Impact of covid-19 Cerebral Embolic Protection Devices for TAVI Market 2020-2027 | Keystone Heart, Claret Medical, Edwards Lifesciences

Global Cerebral Embolic Protection Devices for TAVI Industry: with growing significant CAGR during Forecast 2020-2027 Latest Research Report on Cerebral Embolic Protection Devices for TAVI Market which covers Market Overview, Future Economic Impact, Competition by Manufacturers, Supply (Production), and Consumption Analysis Understand the influence of COVID-19 on the Cerebral Embolic Protection Devices for TAVI Market []

Cheshire Media | September 7, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7174 seconds.